Nurix Therapeutics (NRIX) Liabilities and Shareholders Equity (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $636.1 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $636.1 million, up 3.43% year-over-year; the trailing twelve-month figure through Feb 2026 was $2.4 billion (up 5.6% YoY), and the FY2025 annual result was $688.1 million, up 2.81% from the prior year.
• Liabilities and Shareholders Equity eased to $636.1 million in Q1 2026 per NRIX's latest filing, from $688.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $688.1 million in Q4 2025 and troughed at $308.2 million in Q3 2023.
• A 5-year average of $479.6 million and a median of $459.3 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity sank 32.9% in 2023, then surged 96.7% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $416.8 million in 2022, then decreased by 14.68% to $355.6 million in 2023, then jumped by 88.23% to $669.3 million in 2024, then grew by 2.81% to $688.1 million in 2025, then declined by 7.56% to $636.1 million in 2026.
• Business Quant data shows NRIX's Liabilities and Shareholders Equity at $636.1 million in Q1 2026, $688.1 million in Q4 2025, and $522.5 million in Q3 2025.